Eyenovia
  • Home
  • About
    • About Eyenovia
    • Vision
    • Leadership
  • Technology
  • Pipeline
    • Eyenovia Pipeline
    • MydCombi (Mydriasis)
    • MicroLine (Presbyopia)
    • MicroPine (Myopia)
  • Partners
  • Investors
  • Careers
  • News + Resources
    • News
    • Resource Library
  • Menu Menu

Potential Lost Productivity Resulting from the Global Burden of Myopia

Myopia Control 2020–Where are we and where are we heading

Juvenile Myopia Progression, Risk Factors and Interventions

Five Year Clinical Trial on Atropine for the Treatment of Myopia 2

Facing the Myopia Epidemic

Atropine for treatment of childhood myopia in India (I-Atom)

Recent Posts

  • Eyenovia’s Presentation at the Ladenburg Thalmann Healthcare Conference Wednesday July 14, 2021 July 14, 2021
  • Eyenovia highlights Recent Progress in Three Phase 3 Programs, NDA Review Progress and Licensing Agreements Totaling up to $100 Million in Potential Pre-Commercial Revenue June 15, 2021
  • Eyenovia Announces Positive Topline Results from VISION-1 Phase 3 Clinical Study of MicroLine for the Treatment of Presbyopia May 25, 2021

Pipeline and Technology

  • MydCombi (Mydriasis)
  • MicroLine (Presbyopia)
  • MicroPine (Myopia)
  • Technology

Corporate Address

Eyenovia, Inc.
295 Madison Avenue
Suite 2400
New York, NY 10017
admin@eyenoviabio.com

Copyright © 2021 Eyenovia, Inc. All rights reserved.
  • Twitter
  • Facebook
  • LinkedIn
  • Contact
  • Safe Harbor
  • Privacy Policy
  • Terms of Use
Scroll to top